Consonance Capital Management as of June 30, 2016
Portfolio Holdings for Consonance Capital Management
Consonance Capital Management holds 22 positions in its portfolio as reported in the June 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Mallinckrodt Pub | 13.4 | $95M | 1.6M | 60.78 | |
| Medivation | 10.8 | $77M | 1.3M | 60.30 | |
| Ariad Pharmaceuticals | 9.2 | $65M | 8.8M | 7.39 | |
| Ironwood Pharmaceuticals (IRWD) | 9.1 | $64M | 4.9M | 13.07 | |
| Orthofix International Nv Com Stk | 7.3 | $52M | 1.2M | 42.40 | |
| Retrophin | 6.8 | $48M | 2.7M | 17.81 | |
| Biosante Pharmaceuticals (ANIP) | 6.5 | $46M | 818k | 55.82 | |
| DepoMed | 6.3 | $45M | 2.3M | 19.62 | |
| United Therapeutics Corporation (UTHR) | 6.3 | $44M | 419k | 105.92 | |
| Penumbra (PEN) | 5.8 | $41M | 684k | 59.50 | |
| Clovis Oncology | 5.7 | $40M | 2.9M | 13.72 | |
| Eagle Pharmaceuticals (EGRX) | 2.6 | $19M | 482k | 38.79 | |
| NxStage Medical | 2.6 | $18M | 835k | 21.68 | |
| Cepheid | 2.0 | $14M | 454k | 30.75 | |
| NuVasive | 1.4 | $9.9M | 165k | 59.72 | |
| Pacific Biosciences of California (PACB) | 1.1 | $7.8M | 1.1M | 7.03 | |
| Adma Biologics (ADMA) | 1.1 | $7.6M | 1.3M | 5.95 | |
| Vericel (VCEL) | 0.7 | $5.0M | 2.2M | 2.25 | |
| Axogen (AXGN) | 0.5 | $3.6M | 526k | 6.88 | |
| Seaspine Holdings | 0.4 | $2.7M | 255k | 10.48 | |
| Biolase Technology | 0.2 | $1.5M | 1.3M | 1.17 | |
| Veracyte (VCYT) | 0.1 | $834k | 166k | 5.03 |
